Day One Explored the Bioethics of Drug Development, the Use of
Genomic Technologies for Understanding Disease and the
A new website has been created for journalists with photos of the Convention which may be used in print, broadcast or online stories.
Upcoming Convention Highlights Include:
Please note: This Keynote session is open to attendees who have registered as Convention Access or higher as well as credentialed members of the print media only. No cameras are allowed in the event.
Media Coverage: The event is open to the press. All members of the media who attend the event must check in – and be provided credentials at Media Registration. Names and IDs will be checked. Seating for print media is limited. Once designated seating is full, media will be directed to an overflow room.
Media entrance: Media may enter at the D/E entrances.
Live Truck Pre-Set:
Live truck parking: Satellite trucks may park/stage in front of the
IMPORTANT NOTE: All live trucks must RSVP and request space to gain access. Space is limited and early RSVPs are encouraged.
Cable run: 150 feet
Smart City is able to accommodate fiber and standard cabling.
Smart City may be reached at: email@example.com or 619.525.5524.
IMPORTANT NOTE: Space for cameras is limited. Those planning on covering Secretary Clinton’s remarks must RSVP to gain access. RSVP by
Still Photography Pre-Set:
IMPORTANT NOTE: Those bringing still cameras will be escorted to set location. All photographs will be captured within the first five minutes of the Keynote. RSVP by
Panelists will discuss the dramatic scientific innovation taking place and a vision for new paradigms in oncology through continued scientific investigation, use of new technologies and innovative collaborations.
This year’s BIO/Battelle State Initiatives Report describes the size, scope and performance of the bioscience industry sector at the national, state and metro level and reports on trends in state bioscience industry development efforts. A panel of state Governors will examine in detail a series of key performance metrics and discuss state policies and programs designed to accelerate the growth of the biosciences. The discussion panel will provide an analysis on where the industry stands today and how states can continue fostering a bioscience economy in challenging economic times. This report continues to be a national benchmark for examining the trends in job creation and economic vitality of the biosciences industry – health, agriculture, industrial – in the 50 states,
As investment in new technologies continues to grow, we can expect 2014 to be another showcase year for exciting biotech innovations. Progress in stratified medicine, genomic control and mobile medical technology are changing the way medicine is practiced. Breakthroughs and continuing clinical development in stem cell therapy are bringing us closer to the era of regenerative medicine. Biofuels and industrial enzymes promise to free us from dependence on fossil fuels and lessen our carbon imprint. All of these advances require and are enabled by collaboration between experts from diverse fields. Learn about the most exciting advances of the past year from the experts who translate today’s breakthroughs for the non-scientist professional.
With the forthcoming introduction of biosimilars to the U.S. market, there is debate over the approaches that
Today industry sponsors face two very different criteria for evidence between regulatory bodies and payers. Regulators, such as
BIO IES board members reflect on the 2014 transformation of the industrial biotech sector from pre-commercial promise to market threat – and the unprecedented policy challenges that have accompanied this transition.
Early stage, pre-clinical assets can prove challenging when it comes to determining the value of a particular product or technology. As deals move to earlier stages of development, how do investors approach the valuation of early stage pre-clinical trial assets? Is there a difference between theory and what is practical or achievable? Can you separate intrinsic value from extrinsic competitive value outside your control? Is it possible to find a “win-win” combination so each party can optimize its outcome? This panel will discuss the strategic and economic factors in collaborations, including what unique aspects of products or early stage technology should be considered when pricing transactions. Panelists will offer insight into what to expect and how to weight valuation questions for both emerging companies and larger partners.
The Affordable Care Act has the potential to expand health insurance coverage to millions of individuals, but whether coverage will translate to timely and robust access to care depends on a number of factors, including implementation of the law’s signature health insurance Exchanges.More than 6 months after the first enrollees were eligible to begin receiving care through the Exchanges, this panel will examine access, coverage and reimbursement trends for therapies and specialty care for orphan diseases. Experts will analyze the environment under ACA and provide their perspective on what this law means for the orphan disease patient community and stakeholders in the drug development ecosystem.
No one questions the need to prove value-for-money. But questions remain about the kinds of proof required. The answers vary based on the stakeholders (patients, accountable care organizations or traditional payors, etc.) and therapeutic area (orphan disease or a widespread chronic condition like diabetes). This panel will discuss cases where conventional pharmaceutical wisdom didn't apply. Panelists will compare evidence that has supported past reimbursement decisions and what may be needed in the future, as well as the impact of the changing reimbursement landscape on market access strategies.
Early-stage companies often have limited funds to develop their product. With their focus on regulatory submission, companies often overlook the changing reimbursement environment and don't think about reimbursement requirements early enough. Investors need reassurance that the product under development will be included on managed care formularies when it reaches the market. With payors increasingly requiring evidence demonstrating the economic and clinical value of a product, more data needs to be collected earlier in development to support reimbursement. How can companies allocate their scarce resources between these competing needs? How much evidence of likely reimbursement do investors and potential pharmaceutical partners need when assessing early-stage products? This session will provide guidance for making sense of this evolving reimbursement environment.
As investment in new technologies continues to grow, we can expect 2014 to be another showcase year for exciting biotech innovations. Progress in stratified medicine, genomic control, and mobile medical technology are changing the way medicine is practiced. Breakthroughs and continuing clinical development in stem cell therapy is bringing us closer to the era of regenerative medicine. Biofuels and industrial enzymes promise to free us from dependence on fossil fuels and lessen our carbon imprint. All of these advances require and are enabled by collaboration between experts from diverse fields. Learn about the most exciting advances of the past year from the experts who translate today’s breakthroughs for the non-scientist professional.
Day One Session Highlights Included:
The International BioGENEius Challenge promotes excellence and enables students to continue research in biotechnology and design an original independent research project. This year’s finalists will showcase their research in all-day sessions on days one and two of the Convention, and the winners will be announced at Tuesday Keynote Luncheon.
Speakers at the conference explored how technology advances in sequencing, single-cell analysis, immunotherapy, cell reprogramming and biomaterials are being applied in the context of diverse diseases, including cancer, infectious disease, immune dysfunction and neurodegenerative disorders. The past decade has seen tremendous progress in the use of genome technologies for the detection and interpretation of complex biological processes and for understanding the molecular basis of disease. Speakers focused on how these developments are enabling new approaches to the diagnosis and treatment of a wide array of pathologic conditions. Research on biomaterials offers innovative strategies for translating this knowledge to the clinic.
Follow the 2014 Convention @BIOConvention, and join the conversation @IAmBIOtech.
Media registration is open from
The Convention also features the
Upcoming BIO Events
Livestock Biotech Summit
Pacific Rim Summit on Industrial Biotechnology & Bioenergy
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across
For more information:
Follow us on Twitter @IAmBiotech
Join us on LinkedIn/MyBio
Become a fan at facebook.com/IAmBiotech